CARBON: UAB Cardiovascular Research Biobank
University of Alabama at Birmingham · NCT05067231
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 500
- US sites recruiting
- 1
- Study start
- January 1, 2022
- Record last updated
- February 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.
Conditions: Natriuretic Peptides; Cardiovascular Diseases; Hypertension; Diabetes; Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age more than or equal to 18
Exclusion Criteria
- Age \<18, at screening
- Employees or students associated with the Division of Cardiovascular Disease at UAB will not be recruited due to their vulnerable status and susceptibility to coercion.
- Women who are pregnant or who can become pregnant and not practicing an acceptable method of birth control.
Recruiting US locations
University of Alabama at Birmingham
Birmingham, AL 35294
Site contact: Nehal Vekariya, MS · 205-934-7173 · nvekariya@uabmc.edu
Study contacts (from the official record)
- Nehal Vekariya, MS · 205-934-7173 · nvekariya@uabmc.edu
Similar studies in Alabama
All weight loss studies in Alabama →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Birmingham, AL + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Pelham, AL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Pelham, AL + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Birmingham, AL + 19 other US sites
- Eligibility basics
- Ages 18–75